Estimation of the levels of D-dimer by use of an alternative method based in the reaction time of fibrinogen/fibrin degradation products assay.

Background: D-dimer and fibrinogen/fibrin degradation products (FDP) levels are elevated in thromboembolic disorders, and its assays are used in many laboratories for the investigation of these disorders. The aim of this study was to propose a cost saving alternative method for determination of D-dimer levels based in the reaction time of FDP assay.

Methods: D-dimer and FDP immunoassays were performed in 100 blood samples from subjects by use of Liatest D-dimer and Plasma FDP.

Association between plasma levels of D-dimer and fibrinogen/fibrin degradation products (FDP) for exclusion of thromboembolic disorders.

Background: D-dimer and fibrinogen/fibrin degradation products (FDP) levels are elevated in subjects with thromboembolic disorders, and the assays for detection of D-dimer and FDP are used in many laboratories for the investigation of these disorders. The aim of this study was to evaluate the association between the plasma levels of D-dimer and FDP in the investigation of thromboembolic disorders.

Methods: D-dimer and FDP immunoassays were performed in 217 consecutive blood samples from subjects with suspected of thromboembolic disorders by use of Liatest D-dimer and Plasma FDP.

Lack of association between cardiac troponin T and D-dimer in the evaluation of myocardial damage.

Acute myocardial infarction (AMI) disrupts cardiac cell membranes, releasing intracellular cardiac proteins into the vascular system. Some of these proteins, including the cardiac troponin subunits T and I, have proven useful for diagnosing myocardial damage. Intracoronary thrombosis plays a key role in the pathogenesis of AMI, and the formation of an occlusive thrombus usually precedes the development of myocardial damage.

D-dimer and its relationship to fibrinogen/fibrin degradation products (FDPs) in disorders associated with activation of coagulation or fibrinolytic systems.

Levels of D-dimer and fibrinogen/fibrin degradation products (FDPs) are significantly elevated in patients with deep venous thrombosis, pulmonary embolism, disseminated intravascular coagulation, or other complications. The diagnosis of these disorders can be difficult, time-consuming, and expensive. Assays for the detection of FDPs and D-dimer are used in many laboratories to investigate these disorders.